Equity Profile

TARS

Tarsus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative treatments for eye diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and sales performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative treatments for eye diseases. With a market cap of $3 billion, its work is significant as it addresses unmet medical needs in the pharmaceutical sector, particularly in ophthalmology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1-2026, Tarsus reported an EPS of -$0.16, outperforming analyst expectations by nearly 65%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tarsus's upcoming earnings report, especially after the recent EPS beat. However, the lack of revenue guidance creates uncertainty.

Bull Case

If Tarsus continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or reports wider losses, it could raise concerns about its financial stability and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's market traction and financial health, especially after the last quarter's EPS surprise.

How much is Tarsus investing in R&D this quarter?

R&D spending will indicate the company's commitment to innovation and its ability to bring new products to market, which is vital for long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Tarsus's potential for revenue growth due to its innovative pipeline, which could significantly outperform expectations.

Supporting Evidence

The company's recent EPS surprise indicates stronger-than-expected operational efficiency.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not be reflected in consensus estimates.

Key Risk

If Tarsus announces a new product launch or partnership, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Tarsus's ability to sustain growth against its current financial performance, making these metrics crucial.

Bull Confirmed If

A revenue growth rate of over 20% year-over-year would confirm the bullish outlook.

Bear Confirmed If

If the company reports an EPS loss greater than -$0.20, it would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant movement in Tarsus's stock, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations and raises guidance, history suggests the stock could rise by around 2.5% on the first day.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses expectations, the stock could drop by approximately 2.8%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on partnerships or collaborations that could enhance growth.
3Clarification on revenue projections for the next quarter.
4Insights into market demand for current products.
5Management's outlook on competitive pressures in the ophthalmology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative treatments for eye diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and sales performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1-2026, Tarsus reported an EPS of -$0.16, outperforming analyst expectations by nearly 65%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tarsus's upcoming earnings report, especially after the recent EPS beat. However, the lack of revenue guidance creates uncertainty.

Bull Case

If Tarsus continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or reports wider losses, it could raise concerns about its financial stability and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's market traction and financial health, especially after the last quarter's EPS surprise.

How much is Tarsus investing in R&D this quarter?

R&D spending will indicate the company's commitment to innovation and its ability to bring new products to market, which is vital for long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Tarsus's potential for revenue growth due to its innovative pipeline, which could significantly outperform expectations.

Supporting Evidence

The company's recent EPS surprise indicates stronger-than-expected operational efficiency.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not be reflected in consensus estimates.

Key Risk

If Tarsus announces a new product launch or partnership, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Tarsus's ability to sustain growth against its current financial performance, making these metrics crucial.

Bull Confirmed If

A revenue growth rate of over 20% year-over-year would confirm the bullish outlook.

Bear Confirmed If

If the company reports an EPS loss greater than -$0.20, it would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant movement in Tarsus's stock, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations and raises guidance, history suggests the stock could rise by around 2.5% on the first day.

In-Line / Cautious

A cautious but in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses expectations, the stock could drop by approximately 2.8%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on partnerships or collaborations that could enhance growth.
3Clarification on revenue projections for the next quarter.
4Insights into market demand for current products.
5Management's outlook on competitive pressures in the ophthalmology sector.